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Abstract
Background: Intra-arterial radioembolization with yttrium-90 microspheres ( 90Y-RE) is an increasingly used therapy for 
patients with unresectable liver malignancies. Over the last decade, radioactive holmium-166 poly(L-lactic acid) 
microspheres ( 166Ho-PLLA-MS) have been developed as a possible alternative to 90Y-RE. Next to high-energy beta-
radiation, 166Ho also emits gamma-radiation, which allows for imaging by gamma scintigraphy. In addition, Ho is a 
highly paramagnetic element and can therefore be visualized by MRI. These imaging modalities are useful for 
assessment of the biodistribution, and allow dosimetry through quantitative analysis of the scintigraphic and MR 
images. Previous studies have demonstrated the safety of 166Ho-PLLA-MS radioembolization ( 166Ho-RE) in animals. The 
aim of this phase I trial is to assess the safety and toxicity profile of 166Ho-RE in patients with liver metastases.
Methods: The HEPAR study (Holmium Embolization Particles for Arterial Radiotherapy) is a non-randomized, open 
label, safety study. We aim to include 15 to 24 patients with liver metastases of any origin, who have chemotherapy-
refractory disease and who are not amenable to surgical resection. Prior to treatment, in addition to the standard 
technetium-99m labelled macroaggregated albumin ( 99mTc-MAA) dose, a low radioactive safety dose of 60-mg 166Ho-
PLLA-MS will be administered. Patients are treated in 4 cohorts of 3-6 patients, according to a standard dose escalation 
protocol (20 Gy, 40 Gy, 60 Gy, and 80 Gy, respectively). The primary objective will be to establish the maximum 
tolerated radiation dose of 166Ho-PLLA-MS. Secondary objectives are to assess tumour response, biodistribution, 
performance status, quality of life, and to compare the 166Ho-PLLA-MS safety dose and the 99mTc-MAA dose 
distributions with respect to the ability to accurately predict microsphere distribution.
Discussion: This will be the first clinical study on 166Ho-RE. Based on preclinical studies, it is expected that 166Ho-RE has 
a safety and toxicity profile comparable to that of 90Y-RE. The biochemical and radionuclide characteristics of 166Ho-
PLLA-MS that enable accurate dosimetry calculations and biodistribution assessment may however improve the 
overall safety of the procedure.
Trial registration: ClinicalTrials.gov NCT01031784
Background
The liver is a common site of metastatic disease. Hepatic
metastases can originate from a wide range of primary
tumours (e.g. colorectal-, breast- and neuroendocrine
tumours) [1]. It is estimated that 50% of all patients with a
primary colorectal tumour will in due course develop
hepatic metastases [2]. Once a primary malignancy has
spread to the liver, the prognosis of many of these
patients deteriorates significantly. Potentially curative
treatment options for hepatic metastases consist of sub-
total hepatectomy or, in certain cases, radiofrequency
ablation. Unfortunately, only 20-30% of patients are eligi-
ble for these potentially curative treatment options,
mainly because hepatic metastases are often multiple and
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in an advanced stage at the time of presentation [3]. The
majority of patients are therefore left with palliative treat-
ment options.
Palliative therapy consists primarily of systemic chemo-
therapy. In spite of the many promising developments on
cytostatic and targeted biological agents over the last ten
years, there are still certain tumour types that do not
respond adequately and the long-term survival rate for
patients with unresectable metastatic liver disease
remains low [4-8]. Moreover, systemic chemotherapy can
be associated with substantial side effects that lie in the
non-specific nature of this treatment. Cytostatic agents
are distributed over the entire body, destroying cells that
divide rapidly, both tumour cells and healthy cells. For
these reasons, a significant need for new treatment
options is recognized.
A relatively recently developed therapy for primary and
secondary liver cancer is radioembolization with yttrium-
90 microspheres ( 90Y-RE). 90Y-RE is a minimally invasive
procedure during which radioactive microspheres are
instilled selectively into the hepatic artery using a cathe-
ter. The high-energy beta-radiation emitting micro-
spheres subsequently strand in the arterioles (mainly) of
the tumour, and a tumoricidal radiation absorbed dose is
delivered. The clinical results of this form of internal radi-
ation therapy are promising [9,10]. The only currently
clinically available microspheres for radioembolization
loaded with 90Y are made of either glass (TheraSphere ®,
MDS Nordion Inc., Kanata, Ontario Canada) or resin
(SIR-Spheres ®, SIRTeX Medical Ltd., Sydney, New South
Wales, Australia).
Although  90Y - R E  i s  ev e r m o r e  u s e d  a n d  c o n s i d e r e d  a
safe and effective treatment, 90Y-MS have a drawback: fol-
lowing administration the actual biodistribution cannot
be accurately visualized. For this reason, holmium-166
loaded poly(L-lactic acid) microspheres ( 166Ho-PLLA-
MS) have been developed at our centre [11,12]. Like 90Y,
166Ho emits high-energy beta particles to eradicate
tumour cells but 166Ho also emits low-energy (81 keV)
gamma photons which allows for nuclear imaging. As a
consequence, visualization of the microspheres is feasi-
ble. This is very useful for three main reasons. Firstly,
prior to administration of the treatment dose, a small
scout dose of 166Ho-PLLA-MS can be administered for
prediction of the distribution of the treatment dose. This
provides a theoretical advantage over 90Y-RE, for which
the distribution assessment depends on a scout dose of
99mTc-MAA, with a disputable distribution correlation
with the actual microspheres [13]. Secondly, quantitative
analysis of the nuclear images would allow assessment of
the radiation dose delivered on both the tumour and the
normal liver (i.e. dosimetry) [14]. Thirdly, since holmium
is highly paramagnetic, it can be visualized using mag-
netic resonance imaging (MRI). Quantitative analysis of
these MRI images is also possible, which is especially use-
ful for medium- and long-term monitoring of the intra-
hepatic behaviour of the microspheres [15,16].
The pharmaceutical quality of 166Ho-PLLA-MS has
been thoroughly investigated and proven to be satisfac-
tory [17-19]. Multiple animal studies have been con-
ducted in order to investigate the intrahepatic
distribution (ratio tumour to normal liver), the toxicity
profile/biocompatibility of the 166Ho-PLLA-MS, safety of
the administration procedure, and efficacy of these parti-
cles [20-23].
Now that the preclinical phase of 166Ho-RE has been
successfully completed, we will start a clinical trial (the
HEPAR study: Holmium Embolization Particles for Arte-
rial  Radiotherapy) in order to evaluate 166Ho-RE in
patients with liver metastases. The main purpose of this
trial is to assess the safety and toxicity profile of 166Ho-
RE. Secondary endpoints are tumour response, biodistri-
bution prediction with 99mTc-MAA versus a safety dose




The HEPAR study is a single centre, non-randomized,
open label safety study. In this phase I study, a new device
will be investigated, namely 166Ho-PLLA-MS for intra-
arterial radioembolisation for the treatment of liver
malignancies. In a group of 15 to 24 patients with liver
metastases, treated with increasing amounts of 166Ho, the
device will be investigated for safety and toxicity.
Subjects
The study will include patients with liver-dominant
metastases, of any histology, who cannot be treated by
standard treatment options such as surgery and systemic
chemotherapy, due to advanced stage of disease, signifi-
cant side effects or unsatisfactory tumour response. The
detailed inclusion and exclusion criteria are listed in
Appendix 1.
Time schedule
Patient recruitment will take place between October 2009
and January 2011.
Medical device
Using the solvent evaporation technique, non-radioactive
holmium-165 ( 165Ho) and its acetylacetonate complex
(HoAcAc) can be incorporated into the poly(L-lactic
acid) matrix to form microspheres (Figure 1). Subse-
quently, the non-radioactive 165Ho-PLLA-MS can be
made radioactive by neutron activation in a nuclear facil-
ity and form 166Ho-PLLA-MS. Neutron-activated 166HoSmits et al. Journal of Experimental & Clinical Cancer Research 2010, 29:70
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has a half-life of 26.8 hours and is a beta emitter (Eβmax =
1.85 MeV) that also emits gamma photons (Eγ = 81 keV)
suitable for single photon emission computed tomogra-
phy (SPECT) (Table 1).
Recruitment
Patients with liver metastases who agree to participate in
the study must be referred to the principle investigator by
the department of Surgery. The principle investigator will
inform every patient and obtain their informed consent.
Pre-treatment work-up
Screening
A screening visit will take place at the outpatient clinic
within 14 days prior to the fist angiography. During this
visit, the principle investigator will run through the inclu-
sion and exclusion criteria, conduct a physical examina-
tion, and assess the WHO performance status of the
patient. Subsequently, CT, MRI, and positron emission
tomography (PET) will be performed, as well as electro-
cardiography (ECG). PET will only be performed in FDG-
avid tumours. Liver weight will be calculated, based on
t h e  l i v e r  v o l u m e  m eas u r ed  o n  CT  da t a  wi t h  a  d e n s i t y
conversion factor of 1.0 g/cm 3. Relevant laboratory tests
(haematology, coagulation profile, serum chemistry,
tumour marker) must be documented and reviewed. All
patients are asked to fill out the European Organisation
for Research and Treatment of Cancer (EORTC) QLQ-
C30 questionnaire [24].
Angiography
Patients will be hospitalized on the evening prior to
angiography. On day 0 the patient is subjected to angiog-
raphy of the upper abdominal vessels. The celiac axis and
superior mesenteric artery are visualised, followed by
coiling of relevant vessels, in particular branches of the
hepatic artery supplying organs other than the liver, e.g.
gastroduodenal artery (GDA), right gastric artery (RGA).
If major arteries like the GDA or RGA cannot be success-
fully occluded, the patient will be withheld 166Ho-RE.
This procedure will be performed by a skilled and trained
interventional radiologist. The catheter is introduced
using the Seldinger technique. Prior to the procedure, the
patient is offered a tranquilizer (oxazepam 1 dd 10 mg).
Premedication consists of a single administration of cor-
ticosteroids (dexamethason 10 mg i.v.) and antiemetics
(ondansetron 8 mg i.v.). Proton pump inhibitors (panto-
prazol 1 dd 40 mg) are started on the day of the interven-
tion and prescribed for use until the end of the follow-up.
Macroaggregated albumin injection
After successful angiography and coiling of relevant vas-
culature is performed, a dose of 99mTc-Macroaggregated
Albumin ( 99mTc-MAA) will be administered in the
hepatic artery on the same day. The 99mTc-MAA are used
Table 1: Microsphere characteristics
Microsphere type Ho-PLLA-MS TheraSphere® SIR-Spheres®
Matrix material PLLA Glass Resin
Isotope 166Ho 90Y
Physical half-life (h) 26.8 64.1
Υ-energy (keV) 81 no Υ-emission
β-energy (MeV) 1.77 (48.7%) 1.85 (50.0%) 2.28 (99.9%)
Neutron absorption cross-section (barn) 64 1.3
Activity/sphere (Bq) ≤ 450 2500 50
n particles instilled 33 million 4 million 50 million
Density (g/ml) 1.4 3.3 1.6
Figure 1 Scanning electron microscope image of holmium micro-
spheres.Smits et al. Journal of Experimental & Clinical Cancer Research 2010, 29:70
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to assess whether a favourable distribution of the 166Ho-
PLLA-MS can be expected. The patient is subjected to
planar imaging of the thorax and abdomen and SPECT of
the abdomen, in order to determine the 99mTc-MAA dis-
tribution. Images will be evaluated qualitatively and
quantitatively. Extrahepatic deposition of activity is a
contra-indication for administration of the treatment
dose. Region of interest analysis will be used to calculate
lung shunting. Lung shunting should not exceed 20% of
the dose 99mTc-MAA. If the amount of lung shunting can-
not be reduced to <20% using standard radiological inter-
ventional techniques to decrease the shunting, the patient
will not be eligible to receive a safety nor a treatment dose
of  166Ho-PLLA-MS. The dose point-kernel method will
be applied to the (non-homogeneous) activity distribu-
tion to calculate the absorbed dose distribution [25].
Dose-volume histograms will be generated in order to
quantify the dose distribution, and the tumour to healthy
tissue absorbed dose ratio will be calculated.
166Ho-PLLA-MS safety dose
The second angiography takes place around 1 week after
the first angiography but no longer than 2 weeks later.
Patients will be hospitalized on the evening before the
day of treatment. They will be discharged approximately
48 hours after the intervention unless complications have
occurred. Prior to the procedure, the patient is offered a
tranquilizer (oxazepam 10 mg). A safety dose of 166Ho-
PLLA-MS will be administered through a catheter inside
the hepatic artery, at the position planned during the first
intervention. The safety dose will consist of 60 mg (10%
of the total amount of microspheres) 166HoPLLA-MS
with a lower specific activity (90 Bq/microsphere) than
for the treatment dose. After the safety dose, planar imag-
ing of both the thorax and abdomen will be performed, as
well as SPECT and MRI of the abdomen. Presence of
inadvertent administration to the lungs or other upper
abdominal organs will once more be checked for. These
SPECT and MRI images will be compared with the
images post 99mTc-MAA and post-treatment, regarding
extrahepatic deposition of activity, percentage lung
shunting, homogeneity of the dose distribution and
tumour to healthy tissue absorbed dose ratio.
Treatment
166Ho-PLLA-MS treatment dose
When the amount of lung shunting does not exceed 20%
of the safety dose of 166HoPLLA-MS, the (complete)
treatment dose of 166HoPLLA-MS will be administered
(Figure 2). Consecutive cohorts of 3 patients will be
treated with identical amounts of microspheres (600 mg),
and the last cohort will consist of at least 6 patients. If no
toxicity ≥ grade 3 according to the Common Terminology
Criteria for Adverse Events (CTCAE)[26] is observed, the
next cohort of three patients will be treated at the next
radiation dose level. If in one patient CTCAE ≥ grade 3 is
observed in a particular cohort, the cohort will be
extended to six patients. If toxicity ≥ grade 3 is observed
in two or more patients in a particular cohort, the study
will be terminated because the endpoint, e.g. the maxi-
mum tolerated radiation dose, is reached. This will be
reported to the Independent Ethics Committee (IEC).
The dose level prior to the toxic radiation dose will
become the recommended dose for efficacy studies. If an
event is classified as grade 3 or 4 administration tech-
nique related, the patient will be replaced. The specific
activity of the 166Ho-PLLA-MS will be increased by
adapting the activation time in the nuclear reactor. The
first, second, third and fourth cohort will be treated with
a dose of 1.3, 2.5, 3.8 and 5.0 GBq/kg (liver weight),
respectively. Assuming a homogenous uptake throughout
the liver, this equals escalating radiation doses of 20 Gy,
40 Gy and 60 Gy, to a maximum dose of 80 Gy in the last
cohort. A maximum of 15.1 GBq will be given to the
maximum treated liver weight (inclusive the tumour tis-
sue) of 3 kg (Table 2). The amount of radioactivity admin-
istered to the patient is calculated according to the
following formula:
where LW is the liver weight of the patient which may
be determined using CT, MRI or ultrasound, and where
15.87 × 10 -3 (J/MBq) is the activity-to-dose conversion
factor for 166Ho [23].
Radiation exposure rate
During the hospitalization in week 1 the radiation expo-
sure rate will be measured from 1 m distance at t = 0, 3, 6,
24, and 48 hours following 166Ho-PLLA-MS administra-
tion. Patients will not be discharged from the hospital
until the dose equivalent is less than 90 μSv/h measured
from 1 m distance.
Follow-up
All patients are followed over a period of 12 weeks after
treatment with weekly visits at the outpatient clinic. Dur-
ing each visit, data is collected by physical examination,
WHO performance status assessment and laboratory
examination (haematology, coagulation profile, serum
chemistry and (if applicable) tumour marker). Adverse
events are monitored. In addition, patients are asked to
fill out the EORTC questionnaires in the 6 th and 12 th
week post-treatment. CT and (in case of 18F-FDG-avid
tumours) PET are performed in the 6 th and 12 th week
post-treatment and MRI is performed in the 1 st and the
12 th week post-treatment (Figure 3).
A MBq LW kg Liver Dose Gy 1587 1 J MBq Ho 166
3
−
− ()( ) = () × () // . / 0Smits et al. Journal of Experimental & Clinical Cancer Research 2010, 29:70
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Holmium content
Pooled urine samples will be collected from 0-3 hours, 3-
6 hours, 6-24 hours and 24-48 hours post- 166Ho-PLLA-
MS administration. In the 6 th and 12 th week post treat-
ment, pooled 24-hours urine will be collected for mea-
surement of holmium content. The date and time of the
start and the end of the collection period, the volume and
whether the collection was complete or not, will be noted
in the case record form. During the hospitalization in
week 1, blood will be drawn for measuring the holmium
content in the blood at t = 0, 3, 6, 24, and 48 hours follow-
ing  166Ho-PLLA-MS administration. Measurements will
Figure 2 Schematic overview of the administration system for 166Ho-RE.The administration system consists of the following components: iodine 
contrast agent (Visipaque ®, GE Healthcare) (1), saline solution (2), 20-ml syringe (Luer-Lock) (3), three-stopcock manifold (4), one-way valve (5), inlet 
line (6), administration vial containing the 166Ho-PLLA-MS (7), outlet line (8), flushing line (9), Y-connector (10) and catheter (11).
Table 2: Dose (Gy) and activity (MBq) relation of 166Ho treatment
Liver weight (kg)
11 , 522 , 53
Liver dose (Gy) A (MBq) A (MBq) A (MBq) A (MBq) A (MBq)
10 630 945 1260 1575 1890
20 1260 1890 2520 3150 3780
30 1890 2835 3780 4725 5670
40 2520 3780 5040 6300 7560
50 3150 4725 6300 7875 9450
60 3780 5670 7560 9450 11340
70 4410 6615 8820 11025 13230
80 5040 7560 10080 12600 15120
In bold: the four consecutive cohorts receive 1.3 GBq/kg (20 Gy), 2.5 GBq/kg (40 Gy), 3.8 GBq/kg (60 Gy) and 5.0 GBq/kg (80 Gy), respectively. 
As an example, a patient in the first cohort (20 Gy) with a 1.5-kg liver, will be administered a total activity of 1890 MBqSmits et al. Journal of Experimental & Clinical Cancer Research 2010, 29:70
http://www.jeccr.com/content/29/1/70
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be done according to activity measurement of holmium-
166 metastable ( 166mHo, T 1/2 ≈ 1200 year) with a low-
background gamma-counter (Tobor, Nuclear Chicago,
Chicago, IL, USA) as previously described in one of the
preclinical studies by Zielhuis et al. [19].
Primary objective
The primary objective of this study is to establish the
safety and toxicity profile of treatment with 166Ho-PLLA-
MS. This profile will be established using the CTCAE
v3.0 methodology and will be used to determine the max-
imum tolerated radiation dose. Any of the following
events which are considered possibly or probably related
to the administration of 166Ho-PLLA-MS will be consid-
ered a serious adverse event during the 12 weeks follow-
up period:
• Grade 3-4 neutropenic infection (absolute neutrophil
count < 1.0 × 10 9/L) with fever > 38.3°C,
• Grade 4 neutropenia lasting > 7 days,
• Grade 4 thrombocytopenia (platelet count < 25.0 ×10
9/L),
• Grade 3 thrombocytopenia lasting for > 7 days,
Figure 3 Timeline for study participants. *only in 18F-FDG-avid tumours.Smits et al. Journal of Experimental & Clinical Cancer Research 2010, 29:70
http://www.jeccr.com/content/29/1/70
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• Any other grade 3 or 4 toxicity (excluding expected
AST/SGOT, ALT/SGPT elevation, elevated bilirubin
and lymphopenia) possibly related to study device,
using CTCAE v3.0.
• Any life threatening event possibly related to the study
device: events as a consequence of inadvertent deliv-
ery of 166Ho-PLLA-MS into non-target organs like the
lung (radiation pneumonitis), the stomach and duode-
num (gastric/duodenal ulcer or perforation), the pan-
creas (radiation pancreatitis), and liver toxicity due to
an excessive radiation dose ("radiation induced liver
disease" (RILD) [10]).
The haematological and biochemical adverse events as
well as RILD will be considered dose limiting toxicity.
Secondary objectives
Secondary objectives are to evaluate tumour response,
performance status, biodistribution, quality of life and to
compare the accuracy of the 99mTc-MAA scout dose with
a safety dose of 166Ho-PLLA-MS, in predicting micro-
sphere distribution of the treatment dose. Tumour
response will be quantified using CT of the liver scored
according to Response Evaluation Criteria in Solid
Tumours guidelines (RECIST 1.1) [27]. Tumour viability
will be assessed by PET , depending on tumour type. In
addition, the antitumoral effect will be assessed by rele-
vant tumour markers responses if applicable (i.e. carcino-
embryonic antigen (CEA) in colorectal carcinoma and
chromogranin A (CgA) for neuroendocrine tumours).
Biodistribution is assessed using quantitative SPECT and
MRI. Urine and blood samples will be screened for pres-
ence of 166Ho-PLLA-MS or fragments of 166Ho-PLLA-
MS. Performance status is assessed using WHO perfor-
mance status criteria. Quality of life (QoL) is evaluated
using the EORTC questionnaire QLQ-C30 with colorec-
tal liver metastases module QLQ-LMC21. Finally, the
accuracy of the 166Ho-PLLA-MS safety dose in predicting
the distribution of the treatment dose is compared with
the accuracy of the 99mTc-MAA. Quantitative SPECT
analysis will be performed using the scatter correction
method described by De Wit et al. [14].
Safety profile
From the literature on 90Y-RE, it is known that several
treatment related effects can occur in radioembolization.
As long as the patient is treated with the correct tech-
nique, which includes that no excessive radiation dose be
delivered to any organ, the common adverse events after
receiving radioactive microspheres are fever, abdominal
pain, nausea, vomiting, diarrhoea and fatigue (i.e.
postembolization syndrome) [10,28-30]. These effects are
in general self-limiting within 1 to 2 weeks, and may be
up to grade 3 or 4 (CTCAE v3.0) without direct clinical
relevance. Based on the preclinical studies, a similar
safety profile is expected for 166Ho-RE [22,23].
Escape medication
Patients will receive oral analgesics (paracetamol up to
4000 mg/24 h) for relief of fever and pain after the admin-
istration of microspheres. To reduce nausea and vomit-
ing, patients will receive anti-emetics (ondansetron up to
3 dd 8 mg) during the first 24 hours after administration
of the treatment dose. In the case of persisting nausea,
metoclopramid (up to 300 mg/24 h) will be used. Patients
suffering from diarrhoea will receive loperamide (up to
16 mg/24 h). The vascular contrast agent jodixanol (Visi-
paque ®) may cause renal insufficiency in poorly hydrated
patients. All patients will therefore be hydrated. This con-
sists of 1.5 l NaCl 0.9% both prior to and post angiogra-
phy. Inadvertent delivery of microspheres into organs
such as the lungs, stomach, duodenum, pancreas, and
gallbladder is associated with serious side effects. To
reduce toxicity of the radioactive microspheres in
patients with excessive extrahepatic deposition of 166Ho-
PLLA-MS, the cytoprotective agent amifostine (Ethyol ®,
up to 200 mg/m 2 for 7 days) may be administered intra-
venously.
Statistical considerations
Descriptive statistics (n, mean, standard deviation,
median, minimum and maximum) will be calculated for
each quantitative variable; frequency counts by category
will be made for each qualitative variable. Interim analy-
sis will be performed after every 3 patients. Inclusion of
patients in the next cohort will be performed if the Inde-
pendent Data Monitoring Committee (IDMC) has scruti-
nized the toxicity data and given permission to proceed.
T wo sets of study data will be evaluated: the primary
objective will be evaluated in the full analysis set (FAS).
The FAS is defined as the set of data generated from the
included patients who received at least the safety dose.
The secondary objectives will be evaluated in both FAS
and per-protocol set (PPS). The PPS is defined as the set
of data generated from the included patients who com-
plied with the protocol.
Monitoring
The IDMC will perform a safety review after each series
of treatments of three consecutive patients. The IDMC
members have no conflict of interest with the sponsor
because they are not involved in the study, nor are they
receiving funds. The IDMC will work according to stan-
dard operating procedures and will receive reports on a
regular basis on all toxicity CTCAE ≥ grade 3 reported for
this trial. Recruitment will not be interrupted unless oth-
erwise requested by the chairman of the IDMC. The
responsibilities of the IDMC include:Smits et al. Journal of Experimental & Clinical Cancer Research 2010, 29:70
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• minimize the exposure of patients to an unsafe ther-
apy or dose
• make recommendations for changes in study pro-
cesses where appropriate
• endorse continuation of the study
• inform the institutional IEC in the case of toxicity
CTCAE ≥ grade 3 and/or when the well-being of the
subjects is jeopardized
Ethical considerations
The study will be conducted according to the principles
of the Declaration of Helsinki (version 9.10.2004) and in
accordance with the Medical Research Involving Human
Patients Act (WMO), the requirements of International
Conference on Harmonization - Good Clinical Practice.
The study protocol has been approved by the IEC and by
the institutional Radiation Protection Committee.
Discussion
The HEPAR trial is a phase I study to evaluate the safety
and toxicity profile of 166Ho radioembolization. Second-
ary endpoints are tumour response, biodistribution
assessment, performance status, quality of life and com-
parison of the biodistributions of the 99mTc-MAA scout
dose and the 166Ho-PLLA-MS safety dose.
With regard to the method of administration, viz.
through a catheter placed in the hepatic artery, the in-
vivo characteristics (no significant release of radionu-
clide), and the mechanism of action (local irradiation of
the tumour), 166Ho-PLLA-MS constitute a device analo-
gous to the 90Y microspheres, which are currently applied
clinically. 166Ho-PLLA-MS only differ in the radioisotope
and the device matrix that are used. In a toxicity study in
pigs on 166Ho-RE, it has been demonstrated that (healthy)
pigs can withstand extremely high liver absorbed doses,
at least up to 160 Gy [23]. During these animal experi-
ments, only very mild side effects were seen: slight and
transitory inappetence and somnolence, which may well
have been associated with the anaesthetic and analgesic
agents that had been given and not necessarily with the
microsphere administration. It is plausible that this low
toxicity profile is caused by the inhomogeneous distribu-
tion of 166Ho within the liver after intra-arterial injection,
as was observed on MRI and SPECT images. The current
study will investigate whether a similar distribution pat-
tern can also be observed in human subjects and whether
this inhomogeneous distribution is concentrated around
the tumour sites.
Hepatic arterial injection with 99mTc-MAA and subse-
quent scintigraphic imaging is widely used to predict the
biodistribution of 90Y microspheres, prior to the actual
radioembolization procedure. Its accuracy can however
be disputed. In our centre, we have observed that patients
with a borderline lung shunt fraction of 10% to 19%, as
calculated using the 99mTc-MAA images (approximately
24% of all patients, all of whom were instilled a by 50%
reduced amount of radioactivity), had no signs of lung
shunting on post- 90Y-RE Bremsstrahlung images. In
these cases, it seems that the 99mTc-MAA-scan had false-
positively predicted extrahepatic spread. This may be
explained by the fact that 99mTc-MAA differs in many
aspects from the microspheres that are used. Shape, size,
density, in-vivo half-life, and number of 99mTc-MAA par-
t i c l e s  d o  n o t  r e s e m b l e  t h e  m i c r o s p h e r e s  i n  a n y  w a y
[13,31]. In addition, free technetium that is released from
the MAA particles can disturb the (correct) assessment of
extrahepatic spread. We hypothesize that a small safety
dose with low-activity 166Ho-PLLA-MS will be a more
accurate predictor of distribution than 99mTc-MAA. The
unique characteristics of 166Ho-microspheres, in theory,
allow a more accurate prediction of the distribution with
the use of scintigraphy and MRI. In this study, we chose
to perform both an injection with 99mTc-MAA and
administration of a safety dose of 166Ho-PLLA-MS. The
respective distributions of the 99mTc-MAA and the 166Ho-
PLLA-MS safety dose will be compared with the distribu-
tion of the treatment dose of 166Ho-PLLA-MS by quanti-
tative analysis of the scintigraphic images.
Both commercially available 90Y-MS products are
approved by the F ood and Drug Administration (FDA)
and European Medicines Agency as a medical device and
not as a drug. Radioactive microspheres are a medical
device since these implants do not achieve any of their
primary intended purposes through chemical action
within or on the body and are not dependent upon being
metabolized for the achievement of their primary
intended purpose. In accordance with the definition of a
medical device by the FDA and in analogy with the 90Y-
MS, we consider the 166H o - P L LA - M S  t o  be  a  m e d i c a l
device [32]. The Dutch medicine evaluation board has
discussed this issue (13 July 2007) and has concluded that
the microspheres are indeed to be considered as a medi-
cal device.
One important issue concerning the resin-based SIR-
Spheres  ®  is the relatively high number of particles
instilled (>1,000 mg), since this may sometimes be associ-
ated with macroscopic embolization as observed during
the fluoroscopic guidance [28,33]. Several authors have
reported stasis of flow during administration of resin
microspheres and were forced to end the procedure pre-
maturely because of the risk of backflow, hence extrahe-
patic deposition of a part of the dosage [28,34,35]. The
specific activity of the 166Ho-PLLA-MS is considerably
higher than that of the resin microspheres (≤450 and 50
Bq/microspheres, respectively). However, in order toSmits et al. Journal of Experimental & Clinical Cancer Research 2010, 29:70
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obtain an equivalent absorbed dose, the total amount of
radioactivity of the administered microspheres in 166Ho
radioembolization needs to be 3 times higher than in 90Y
radioembolization, due to the shorter physical half-life of
166Ho. Even so, compared with the resin 90Y micro-
spheres, in 166Ho radioembolization considerably less
microspheres (≤600 mg) are used to obtain an equivalent
radiation dose, resulting in a lower risk of stasis or back-
flow during administration [9,29]. A further issue is that
90Y microspheres can not be visualized under fluoroscopy
during injection. Manufacturers of resin 90Y micro-
spheres state that their microspheres are to be adminis-
tered with water for injection alternated with non-
ionogenic contrast [36]. As a result, the operating physi-
c i a n  c a n n o t  d e t e c t  s t a s i s  o r  b a c k f l o w  o f  m i c r o s p h e r e s
until he has switched from injecting microspheres to
injecting the contrast agent. Holmium microspheres, on
the contrary, are administered in a mixture of 50% saline
and 50% non-ionogenic contrast under constant fluoro-
scopic imaging, which ensures constant control over the
microspheres during injection [37]. However, continuous
fluoroscopic imaging during microsphere administration
may comprise an increased radiation dose delivered to
the patient, specifically the abdominal skin, during the
procedure. 
If this phase I trial provides sufficient data to prove that
166Ho-PLLA-RE has an acceptable safety and toxicity pro-
file, further studies will be needed. The next step will be
an efficacy study in a larger number of patients. The pri-
mary endpoints of t ha t st udy will be t umour response
and survival.
Appendix 1 - Eligibility criteria for 166Ho-RE
Inclusion criteria
• Signed informed consent letter
• Age >18 years
• Liver-dominant metastases without standard treat-
ment options. Liver-dominant disease is defined as 
the diameter of all metastases in the liver to be more 
than 200% of the sum of the diameters of all soft tis-
sue lesions outside the liver.
• Life expectancy of ≥12 weeks
• World Health Organisation (WHO) Performance 
status 0-2
• ≥1 measurable lesions of ≥10 mm in the longest 
diameter by spiral computed tomography (CT) (5 
mm slice thickness)
• Negative pregnancy test for women
Exclusion criteria
• Brain metastases or spinal cord compression, unless 
irradiated at least 4 weeks prior to the date of the 
experimental treatment, and stable without steroid 
treatment for at least 1 week
• Radiation therapy within the last 4 weeks before 
study enrolment
• Patient has received chemotherapy within 4 weeks 
prior to enrolment
• Major surgery within 4 weeks, or incompletely 
healed surgical incision before enrolment
• Any unresolved toxicity greater than National Can-
cer Institute (NCI), Common Terminology Criteria 
for Adverse Events (CTCAE version 3.0)[26] grade 2 
from previous anti-cancer therapy
• Alanine aminotransferase (ALT), aspartate amin-
otransferase (AST), or alkaline phosphatase (ALP) 
>5× Upper Limit of Normal (ULN), serum bilirubin 
>1.5× ULN or serum creatinine >185 μmol/L
• Leukocytes <4.0 10 9/l and/or platelet count <150 10 
9/l
• Significant cardiac event (e.g. myocardial infarction, 
superior vena cava (SVC) syndrome, New York 
Heart Association (NYHA) classification of heart 
disease ≥2 within 3 months before entry, or pres-
ence of cardiac disease that, in the opinion of the 
investigator, increases the risk of ventricular 
arrhythmia
• Pregnancy or breast feeding
• Comorbidity with a grave prognosis (estimated sur-
vival <3 months) and/or worse than the basic dis-
ease for which the patients will be included in the 
study
• Abnormalities of the bile ducts (such as stents) with 
an increased chance of infection
• Diseases with an increased chance of liver toxicity, 
such as primary biliary cirrhosis or xeroderma pig-
mentosum
• Patients who are declared incompetent or have a 
psychiatric disorder that makes a comprehensive 
judgement impossible, such as psychosis, hallucina-
tions and/or depression
• Previous enrolment in the present study or previous 
treatment with radioembolization
• Treatment with an investigational agent within 42 
days prior to enrolment
• Female patients who are not using an acceptable 
method of contraception or are less than 1 year 
postmenopausal or surgically sterile during their 
participation in this study (from the time the con-
sent form is signed) to prevent pregnancy
• Male patients who are not surgically sterile or do not 
use an acceptable method of contraception during 
their participation in this study to prevent preg-
nancy in a partner
• Evidence of portal hypertension, splenomegaly or 
ascites
• Body weight >150 kg
• Active hepatitis (B and/or C)Smits et al. Journal of Experimental & Clinical Cancer Research 2010, 29:70
http://www.jeccr.com/content/29/1/70
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• Liver weight >3 kg (determined by software using 
CT data)
• Allergy for intravenous contrast agent used (Visi-
paque ®)
• General MRI contra-indications (severe claustro-
phobia, metal implants, implanted pacemaker and/
or neurostimulators)
• Patients who have arterial variations that will not 
allow whole liver treatment by a single administra-
tion via the hepatic artery
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